Tolerability and Safety of CARDIOMEMS™ Intracardiac Continuous Cardiac Hemodynamic Monitoring Device in Patients with Cardio Renal Syndrome with Severe Renal Impairment

Inclusion Criteria: * Patient with class NYHA III heart failure having been hospitalized in the previous 12 months for cardiac decompensation (the current indication for the CARDIOMEMS™ system), right heart failure or biventricular heart failure with the definition of TAPSE\<15mm and/or SDTI\<9.5cm/s regardless of LVEF, NtproBNP\>1500 pg/ml. * Patient with advanced renal failure with GFR (CKD-EPI) \< 30 ml/min/1.73m2 for more than 3 months confirmed by GFR measurement (Iohexol clearance) * Patient with a pulmonary artery greater than 7 mm in diameter. * The patient has been informed of the study set-up, objectives, constraints and patient rights. * The patient must have given free and informed consent and signed the consent form. * The patient must be affiliated or a beneficiary of a health insurance plan. Precautions: if the patient is on anticoagulant therapy, an International Normalized Ratio \<1.5 is recommended before right heart catheterization and any implantation procedure Exclusion Criteria: * Patients with a contraindication to the CARDIOMEMS™ HF system (pulmonary embolism with sequelae, artery less than 7 mm, active infection). * Patients already on renal replacement therapy. * Patients with a history of acute venous thrombosis. * Patients unable to tolerate right heart catheterization. * Patients with a major cardiovascular event (i.e., myocardial infarction, stroke) within 2 months of the initial examination. * Patients with congenital heart disease or mechanical right heart valve(s). * Patients with known hypersensitivity or allergy to aspirin and/or clopidogrel. * Patients with a body mass index \>35. Measure the patient's chest circumference at the armpit: if the patient's chest circumference is \> 165 cm, the sensor should not be implanted. * Patients unable to take dual anti-platelet therapy or anticoagulant therapy for one month after implantation * Patient hypersensitive or allergic to iohexol. * Patient is participating in another Class I interventional study, or has participated in another interventional study within the last 3 months. * Patient is in an exclusion period determined by a previous study. * Patient is under guardianship, conservatorship, or conservatorship. * The patient refuses to sign the consent form. * It is impossible to give the patient informed information. * The patient is pregnant or nursing.